Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 6 member 19 (SLC6A19), also known as broad neutral amino acid transporter 1 (B0AT1), is a sodium-dependent, chloride-independent symporter primarily expressed in the apical membrane of renal proximal tubules and intestinal epithelial cells. It plays a critical role in the absorption and reabsorption of neutral amino acids, including phenylalanine, tryptophan, and branched-chain amino acids. For its proper trafficking and functional expression, SLC6A19 requires association with accessory proteins, specifically angiotensin-converting enzyme 2 (ACE2) in the intestine and collectrin (CLTRN) in the kidney. Loss-of-function mutations in the SLC6A19 gene cause Hartnup disorder, a rare autosomal recessive condition characterized by neutral aminoaciduria, pellagra-like skin rashes, and cerebellar ataxia, though many individuals remain asymptomatic.
In therapeutic development, SLC6A19 has emerged as a highly promising target for metabolic and renal diseases. Inhibiting SLC6A19 prevents the reabsorption of phenylalanine in the kidneys, promoting its excretion in urine and thereby lowering toxic systemic levels in patients with phenylketonuria (PKU). Additionally, SLC6A19 inhibition has shown potential in treating type 2 diabetes, obesity, and chronic kidney disease (CKD) by modulating systemic amino acid levels, improving glucose tolerance, and reducing renal transport burden. Novel small-molecule inhibitors, such as repinatrabit (JNT-517) and MZE-782, target allosteric sites on the transporter to lock it in an inactive conformation, and are currently undergoing clinical evaluation.
Allosteric inhibition of the transporter to block the reabsorption and absorption of neutral amino acids, particularly phenylalanine
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 6 member 19 (SLC6A19).